Studies diagnosis and treatment of transthyretin amyloid heart disease
Studies diagnosis and treatment in adults with ATTR cardiomyopathy or their gene carriers.
Plain-language title generated from the registry record
Registry title: Clinical Study of ATTR-CM
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04935021, who can take part
Where in China
- xiaohong University PANHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT04935021
- Record updated
- 31 January 2023
- Original description
In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.Read full original descriptionShow less
Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers
In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.
Inclusion: Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old; Patients who have the ability to understand the test and can cooperate with investigators.
Exclusion: Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors.